ANUH PHARMA LTD. - 506260 - Closure of Trading Window
Intimation regarding the Closure of Trading Window for dealing in Securities of the Company shall remain closed from Monday, July 01, 2024 till the expiry of 48 hours after the declaration of Unaudited Financial Results for the Quarter ended June 30, 2024. ANUH PHARMA LTD. - 506260 - Announcement under Regulation 30 (LODR)-Acquisition
Disclosure for investment in Huoban Energy 5 Private Limited a Special Purpose Vehicle, for Solar Projects under group captive model through open access has been signed by the parties to the Agreement on 31st May, 2024. ANUH PHARMA LTD. - 506260 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Submission of Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2024. ANUH PHARMA LTD. - 506260 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of the Audited Financial Results for the Quarter and Year ended 31st March, 2024, published in the Financial Express in English Language and Mumbai Lakshadeep in Marathi Language on 18th May, 2024. ANUH PHARMA LTD. - 506260 - Results-Financial Year Ended 31St March, 2024
Results for Financial year ended 31st March, 2024 ANUH PHARMA LTD. - 506260 - Announcement under Regulation 30 (LODR)-Change in Management
Appointment of General Manager-Works ANUH PHARMA LTD. - 506260 - Board Meeting Outcome for Board Meeting Outcome Board Meeting Held On 17/05/2024
TO consider and approve the Audited Financial Results for the Financial Year ending 31st March, 2024, recommendation of Dividend for the Financial Year, 2023-24 and Fixation the date of AGM pf the Company. ANUH PHARMA LTD. - 506260 - Board Meeting Intimation for Consideration And Approval Of Audited Financial Results For The Financial Year Ended 31St March, 2024 And Recommendation Of Final Dividend, If Any, For The Financial Year 2023-24.
ANUH PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 ,inter alia, to consider and approve Audited Financial Results for the Quarter and Financial Year ended 31st March, 2024 and recommendation of Final Dividend, if any, for the Financial Year 2023-24. ANUH PHARMA LTD. - 506260 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyANUH PHARMA LTD. 2CIN NO.L24230MH1960PLC011586 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NIL 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Manan Vadhan Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Darshan Rampariya Designation: Chief Financial Officer EmailId: [email protected] Date: 29/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. ANUH PHARMA LTD. - 506260 - Compliances-Compliance Certificate For The Financial Ended 31St March, 2024
Compliance Certificate pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 being received from RTA for the Financial Year ended 31st March, 2024.